

UNITED STATE DEPARTMENT OF COMMERCE Patent and Tragemark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

09/272,764 CLIFFORD KEN THOMAS JEFFE OFFICE OF UN 1020 WALNUT	03/19/99			
CLIFFORD KEN THOMAS JEFFE OFFICE OF UNIT	• = : :	SHI		01 NP001 EXAMINER
THOMAS JEFFE OFFICE OF U			<u> </u>	
THOMAS JEFFE OFFICE OF U	•	QM32/0316	JAWOKSKI, F	PAPER NUMBER
OFFICE OF U	NT WEBER	citV	•	2
LOOK MALMIT	ERSON UNIVER	BUNSEL	0707	•
I O TO 100 100 100 1	STREET SULI	E 620	DATE MAILED:	
PHILADELPHI	A PA 19107-5	5587	0	3/16/00
This is a communication for COMMISSIONER OF PAT	om the examiner in cha ENTS AND TRADEMA	rge of your application. RKS		
		OFFICE ACTION SUMMARY		
Responsive to commun	nication(s) filed on	3-19-99		•
_				
This action is FINAL.				
Since this application is	in condition for allow	vance except for formal matters, prosecu Quayle, 1935 D.C. 11; 453 O.G. 213.	ruon as to the merits is	s Ciosea III
.136(a). isposition of Claims	. /			1
				ing in the application.
Of the above, claim(s)				n from consideration.
Claim(s)	/-	<u> </u>		_is/are allowed. _ts/are rejected.
Claim(s)	<u> </u>			_is/are objected to.
-		are	subject to restriction or	
The drawing(s) filed on	correction, filed on _		ted to by the Examiner.	disapproved.
The oath or declaration	n is objected to by the	Examiner.	•	•
riority under 35 U.S.C. §				
riority under 35 U.S.C. §		eign priority under 35 U.S.C. § 119(a)-(d).		
riority under 35 U.S.C. §	ade of a claim for fore	ign priority under 35 U.S.C. § 119(a)-(d).	have been	
riority under 35 U.S.C. § Acknowledgment is ma	ade of a claim for fore		have been	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applica	ade of a claim for fore None of the CEF ation No. (Series Cod	RTIFIED copies of the priority documents	<u> </u>	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applica	ade of a claim for fore None of the CEF ation No. (Series Cod	RTIFIED copies of the priority documents	<u> </u>	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applica	ade of a claim for fore None of the CEF ation No. (Series Cod ational stage applicati	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Ro	<u> </u>	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applicative received in this na *Certified copies not received.	ade of a claim for fore None of the CEF ation No. (Series Coc ational stage applicati selved:	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Ro	ule 17.2(a)).	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applicate received in this na *Certified copies not received. Acknowledgment is ma	ade of a claim for fore None of the CEF ation No. (Series Coc ational stage applicati selved:	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Re	ule 17.2(a)).	
rlority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applica received in this na *Certified copies not received. Acknowledgment is ma	ade of a claim for fore None of the CEF ation No. (Series Cod ational stage applicational stage applications selved: ade of a claim for dor	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Re	ule 17.2(a)).	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applicate received in this na *Certified copies not received acknowledgment is mattachment(s) Notice of Reference Ci	ade of a claim for fore None of the CEF ation No. (Series Cod ational stage applicational stage applicational stage applications ade of a claim for dor dited, PTO-892	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Re	ule 17.2(a)).	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applicate received in this na *Certified copies not received acknowledgment is mattachment(s) Notice of Reference City	ade of a claim for fore None of the CEF ation No. (Series Cod ational stage application selved: ade of a claim for dor ade of a claim for dor atited, PTO-892 Statement(s), PTO-	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Re nestic priority under 35 U.S.C. § 119(e).	ule 17.2(a)).	
riority under 35 U.S.C. § Acknowledgment is ma All Some* received. received in Applicate received in this nate acknowledgment is material. Acknowledgment is material. Notice of Reference Cit. Information Disclosure	ade of a claim for fore None of the CEF ation No. (Series Cod ational stage application selved: ade of a claim for dor sited, PTO-892 Statement(s), PTO-	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Re nestic priority under 35 U.S.C. § 119(e).	ule 17.2(a)).	
riority under 35 U.S.C. \$ Acknowledgment is ma All Some* received. received in Applica received in this na *Certified copies not received in this ma *Interview Summary, Planta Summary,	ade of a claim for fore None of the CEF ation No. (Series Cod ational stage application relived: ade of a claim for dor sited, PTO-892 Statement(s), PTO- TO-413 s Patent Drawing Rev	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Re nestic priority under 35 U.S.C. § 119(e). I Sheet 1449, Paper No(s).	ule 17.2(a)).	
riority under 35 U.S.C. \$ Acknowledgment is ma All Some* received. received in Applica received in this na *Certified copies not received. Acknowledgment is ma *ttachment(s) Notice of Reference Ci Information Disclosure Interview Summary, P1 Notice of Draftperson's	ade of a claim for fore None of the CEF ation No. (Series Coc ational stage application elived: ade of a claim for dor sited, PTO-892 Statement(s), PTO- TO-413 s Patent Drawing Revent Application, PTO-	RTIFIED copies of the priority documents le/Serial Number) on from the International Bureau (PCT Re nestic priority under 35 U.S.C. § 119(e). I Sheet 1449, Paper No(s).	ule 17.2(a)).	

Art Unit: 3737

1. Claims 1-5 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

With respect to claim 1 the claim recites the intended or desired results as opposed to the method steps of applying...'., 'measuring...', and the ultrasound system is recited as structure as opposed to a step of 'transmitting....with an ultrasound system...(and).....receiving...'.

Additionally the terms sub(ultra)harmonic are vague in context since the transmit portion has not been established to operate at a fundamental frequency soas to define any harmonics. This issue carries forward throughout the claims.

With respect to claim 2, the fundamental frequency issue applies. Additionally the claim is incomplete since the preamble recites measurement of pressure change whereas the body of the claim infers a pressure estimation. Additionally it is unclear how the 'at least one..transducer' relates to the transmitting/receiving since every ultrasound system needs same to have basic function.

With respect to claim 3, the claim is incomplete for purposes of the preamble since no structure for pressure change measurement is recited.

With respect to claim 4, it is unclear from the language 'containing' whether an open (comprising) or closed (consisting of) construct is intended. Additionally it is not completely clear that the microbubbles are adapted for physiologic measurement as opposed to industrial use since the stipulation that the bubbles have size uniformity if placed in a mammalian bloodstream does

Art Unit: 3737

not appear to exclude usage elsewhere under one interpretation whereas under another equally reasonable it does exclude in vitro usage be it hemodialysis or bloodbag or cardiopulmonary bypass or industrial pipe testing.

With respect to claim 5, the 'applying/measuring' issue regarding claim 1 applies. Additionally the 'application' step is vague insofar as the preamble is specific to the estimation of pressure change within a mammal. For example would the external application of a microbubble solution to chamber of a manometric pressure line extending from the patient and equilibrated via a diaphragm be embraced by the claim? Additionally it is unclear whether the measurement step is carried out using the ultrasound system since it is stated only to be involved with signal receipt.

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.
- 3. Claims 2-3 are rejected under 35 U.S.C. 102(e) as being anticipated by Miwa (US4483345). Miwa teaches use of a native cavitation phenomenon wherein microbubbles are generated by low frequency 10khz sweep across their resonance as per Fig. 1 and col. 1 lines 57-63, and the critical cavitation pressure Pc may, with known ambient pressure Pa serve in the col. 4 line 40 equation to determine arterial pulse pressure at the measurement time Pp(tc). Referring to Fig. 7, this scheme is incorporated into a measurement system and method wherein 1 is the sweep

Art Unit: 3737

resonator inducing cavitation for the microbubble formation which is detected by array 5 in conjunction with doppler bandpass filtering to extract high or low frequency harmonics (Abstract and col. 10 lines 5-16). The Col. 7 lines 40-44 array teaching wrt element 5 suffices to additionally reject claim 3.

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- Claims 2, 4-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tickner (US4265251) in view of Sliwa, Jr. et al (US5749364). Tickner in Fig. 4 is directed to a non-imaging single-transducer ultrasound system using an injectate of uniform size microbubbles as per col. 3 lines 6-33 with analog filtering 42 soas to provide an output proportional to resonance frequency and therefore to pressure. It would have been obvious in view of Sliwa, Jr. et alas per col. 2 lines 11-35 to utilize sub or super-harmonics to perform the pressure measurement in Tickner since this puts the returned signals outside the range of the fundamental interrogating pulse for the measurement.
- 6. With respect to composition claim 4, this claim is met by the cited passages in Tickner and Sliwa, Jr,. et al and the inherent property of compressibility of gases within a fluid. Alternately stated, Tickner poses a compositional solution which provides small uniform sized bubbles with left-to-right cardiovascular passage stability. Bubble compressibility is inherent since they are

Art Unit: 3737

gas-filled and exist within a liquid and resonate. This resonance is a natural phenomenon centered upon the harmonics such that Sliwa Jr. et al merely calls this to light.

- 7. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Tickner in view of Sliwa Jr. et al as applied to claims above, and further in view of Schlief et al (US5195520), insofar as the latter teaches that both amplitude and frequency changes may be evaluated in order to ascertain pressure in the medium under test using microbubble scatterers.
- 8. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Tickner in view of Sliwa, Jr. et al as applied to claims above, and further in view of Miwa as per col. 7 lines 40-44 since the attendant advantage of an array to provide directionality to ribcage interrogation of the heart (In Fig. 7 element 5 cooperates in positional registry with secondary scanner 50 to provide directionality as specified by line cursor on display 56) would be useful for Tickner to interrogate the heart from a confined intercostal space pulse emission point..
- 9. Claims 1-5 are rejected under 35 U.S.C. 102(e) as being anticipated by Sliwa, Jr. et al, insofar as array 26 is used to ensonate contrast agents for harmonic effects col. 1 line 37 col. 2 line 59 with measurement of amplitude and/or resonant frequency changes col. 5 lines 63-67 and col. 6 line 45 col. 7 line 23.
- 10. Wheatley (US5352436) is cited for its uniform bubble population size teaching Fig. 1 and the proportional graph for contrast agent echo amplitude versus dosage Fig. 2.
- 11. Katakura et al(US5535747) and Horton (US3640271) are less relevant teachings of the use of microbubbles in physiologic pressure measurements.

Art Unit: 3737

12. Any inquiry concerning this communication should be directed to Examiner Francis J. Jaworski at telephone number (703) 308-3061.

Francis Jaworski Primary Examiner

FJJ:fjj

1-24-00